Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents

We present an interim analysis of a registered clinical study (NCT04800133) to establish immunobridging with various antibody and cellular immunity markers and to compare the immunogenicity and reactogenicity of 2-dose BNT162b2 and CoronaVac in healthy adolescents as primary objectives. One-dose BNT...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosa Duque, Jaime S., Wang, Xiwei, Leung, Daniel, Cheng, Samuel M. S., Cohen, Carolyn A., Mu, Xiaofeng, Hachim, Asmaa, Zhang, Yanmei, Chan, Sau Man, Chaothai, Sara, Kwan, Kelvin K. H., Chan, Karl C. K., Li, John K. C., Luk, Leo L. H., Tsang, Leo C. H., Wong, Wilfred H. S., Cheang, Cheuk Hei, Hung, Timothy K., Lam, Jennifer H. Y., Chua, Gilbert T., Tso, Winnie W. Y., Ip, Patrick, Mori, Masashi, Kavian, Niloufar, Leung, Wing Hang, Valkenburg, Sophie, Peiris, Malik, Tu, Wenwei, Lau, Yu Lung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9240007/
https://www.ncbi.nlm.nih.gov/pubmed/35764637
http://dx.doi.org/10.1038/s41467-022-31485-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9240007/
https://www.ncbi.nlm.nih.gov/pubmed/35764637
http://dx.doi.org/10.1038/s41467-022-31485-z

Ejemplares similares